Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer. Anna will join and…
More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.
LifeArc CEO Dr Melanie Lee welcomes the Government’s restatement of its commitment to increase R&D funding in today’s Autumn statement: “Today the Chancellor made it clear that UK life science is a key driver of growth. “I am delighted that promises to raise the research and development (R&D) budget have been protected. It is the […]
LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
Seed funding will be used to scale the solution through the application of machine learning
Ahead of the Autumn Statement, LifeArc and other leading life science organisations have written to the Chancellor…
The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS